Recommended treatments include emollients and intermittent use of topical corticosteroids. For those with moderate-to-severe disease and where topical therapy fails, oral immunosuppressive treatments, for example, prednisolone, ciclosporin, azathioprine and methotrexate are used and while effective, apart from methotrexate, long-term use of oral treatments is not recommended.2 The introduction of the first monoclonal antibody dupilumab, in August 2019, for patients with moderate-to-severe AE was a major treatment advance although a proportion of patients do not achieve a satisfactory response from the drug,3 hence the need for alternative and effective therapeutic options.
In recent years much interest has centred on a new-class of drugs, the Janus kinase inhibitors (JAKis) of which there are three (tofacitinib, baricitinib and upadacitinib) currently licensed for rheumatoid arthritis and psoriatic arthritis (tofacitinib only). The Janus kinase (JAK) pathway facilitates transmission of chemical signals from outside of the cell (that is, once a ligand binds to its receptor) to the nucleus and the subsequent activation of genes involved in a variety of processes such as immune cell division, activation, recruitment and in the context of AE, inflammation. The Janus family consists of four receptor-associated kinases (JAK1, JAK2, JAK3 and TYK2) and a signal transducer and activator of transcription (STAT) pathway. While the precise aetiology of AE remains to be determined, it is characterised by barrier impairment which is thought, in part due to an exaggerated T-helper 2 (Th2) cell response. Keratinocytes activate dendritic and Langerhans cells which subsequently stimulate Th2 cells to produce a range of pro-inflammatory cytokines including interleukin (IL)-4, IL-5, IL-13, IL-31 and IL-33.4 Furthermore, both IL-4 and IL-13 activate the JAK-STAT pathway, leading to the production of pro-inflammatory cytokines5 and through their action on gene expression, downregulate the production of many of the proteins essential for skin-barrier function.6 As a result, JAKis have a potentially important role in attenuating the downstream activation of many different inflammatory cytokines, hence their role in rheumatoid arthritis. However, the recent publication of the results from two Phase III trials, suggest that oral JAKis represent a potentially important new development in the management of moderate-to-severe atopic eczema.
Clinical studiesThe first trial involved baricitinib, which inhibits JAK1 and JAK2. In two identical, double-blind, 16-week, Phase III trials, 1239 adults with moderate-to-severe AE who had failed to adequately respond to topical therapies, received either placebo, or 1, 2 or 4mg oral baricitinib daily.7 Emollients were allowed throughout the trial but any other oral or topical therapies were stopped but permitted as rescue treatment if required. The primary outcomes were an investigator global assessment (IGA) score of 0 (clear) or 1 (almost clear) and a > 2-point improvement from baseline in IGA score. After 16 weeks, 16.8% of patients taking baricitinib 4mg achieved the primary outcome, 11.4% (baricitinib 2mg) and 11.8% (baricitinib 1mg) compared with 4.8% in the placebo group. Baricitinib 4mg was most effective and improvements in itch, sleep disturbance and skin pain were evident after one week of treatment.
The second trial involved abrocitinib (a JAK1 inhibitor) with 391 patients, aged 12 years and over, given the drug at a daily dose of 200mg or 100mg compared with placebo for 12 weeks.8 As in the baricitinib trials, all patients had a documented inadequate response to topical corticosteroids and topical calcineurin inhibitors. The study employed the same primary outcome measures as the baricitinib trials. At the study end, 38.1% of those given abrocitinib 200mg achieved the primary outcome, 28.4% (abrocitinib 100mg) vs 9.1% in the placebo group. As with baricitinib, patients receiving abrocitinib, improvements in signs and symptoms of AE, were apparent within two weeks. Trials of a third agent, upadacitinib, which is also a JAKi, are underway.
In terms of adverse effects, these occurred in up to 58% of patients receiving baricitinib 4mg although no more than 2.5% of these, which included nasopharyngitis and upper respiratory tract infections, were considered as severe. In the abrocitinib trial, 65.8% of those given the 200mg dose experienced an adverse effect, compared to 62.7% in the lower dose group and 53.8% in those taking placebo. The most common adverse effect was nausea in the high dose groups (14.2%), followed by nasopharyngitis (7.7%).
Place in therapyTo date, the information on the efficacy of JAKis in the management of atopic eczema is promising but limited. There are several Phase II studies of other oral and topical JAKis and the results from Phase III studies of these agents are eagerly awaited. Nevertheless, there is a need for studies to assess the longer-term effectiveness of this class of drugs and if there are any important trade-offs between efficacy and safety. None of these agents are currently licensed for the use of atopic eczema and there is an FDA black box warning for the risk of severe infection with baricitinib 2mg (brand name Olumiant) when used for rheumatoid arthritis.9 It is also important to ascertain where this class might sit in the treatment hierarchy. Despite these reservations, it is likely that JAKis represent a potentially useful addition to the treatment armamentarium of doctors managing patients with atopic eczema and their introduction, once it occurs, should be welcomed.
References
Continue reading here:
JAK inhibitors: a major advance in the treatment of atopic eczema - Hospital Healthcare Europe
- The Compression Fracture of Thoracic Spine Due to Methotrexate-Associated Lymphoproliferative Disorder in Rheumatoid Arthritis: A Case Report - Cureus - February 15th, 2025
- Rheumatoid arthritis tied to cognitive decline in dementia - Medical Xpress - February 15th, 2025
- Tools and Devices to Improve Life and Mobility With Arthritis - U.S. News & World Report - February 15th, 2025
- Actor Adam Thomas Reveals How 'Eating Nothing But Meat and Eggs' is Easing his Arthritis Pain But These Are the Risks - Men's Health UK - February 15th, 2025
- New insights into the association between arthritis and overactive bladder in NHANES 20052020 - Nature.com - February 15th, 2025
- Rheumatoid Arthritis Treatment Market to Hit US$ 79.1 Billion - openPR - February 15th, 2025
- Psoriatic Disease, TNF Inhibitors, and Risk of Major Adverse Events - Medpage Today - February 15th, 2025
- The best treatments for arthritic knees if you want to avoid knee replacement surgery - The Telegraph - February 15th, 2025
- Early Launch Metrics Indicate UCBs Bimzelx (bimekizumab) Poised to Disrupt the U.S. Psoriatic Arthritis Market - GlobeNewswire - February 15th, 2025
- Rosnilimab shows promise in rheumatoid arthritis trial - Investing.com - February 15th, 2025
- 5 foods that keep your joints strong and healthy - Mint - February 15th, 2025
- If You Have Arthritis, This New Makeup Brand Is for You - Money Talks News - February 15th, 2025
- Lower Your Risk Of Rheumatoid Arthritis With These 5 Basic Habits - mindbodygreen - February 15th, 2025
- 'I treat top athletes with arthritis - cupboard staple ingredients are quite effective for pain and swelling' - GB News - February 15th, 2025
- AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment - Yahoo - February 15th, 2025
- Rheumatology enters the chat: research projects use AI and collaborative thinking to improve patient care - University of Alberta - February 15th, 2025
- In Patients with HS, a Closer Look at Stigmatization and Perceived Health Status - Medpage Today - February 15th, 2025
- Psoriatic Arthritis Treatment Market is Set To Fly High in Years to Come: AbbVie Inc., Amgen Inc., Johnson & - EIN News - February 15th, 2025
- Sandoz Rolls Out Rival Version Of AbbVie's Arthritis Drug Humira - BW Healthcare World - February 15th, 2025
- GSK To Bounce Regulatory Submissions For Experimental Arthritis Drug - BW Healthcare World - February 15th, 2025
- Living With Arthritis: Health Information Basics for You and Your ... - January 27th, 2025
- Rheumatoid Arthritis: Diagnosis, Treatment, and Steps to Take - January 27th, 2025
- Rheumatoid Arthritis | Health Topics | NIAMS - January 27th, 2025
- 6 Things to Know About Psoriatic Arthritis - Hartford HealthCare - January 27th, 2025
- MAPK4 inhibits the early aberrant activation of B cells in rheumatoid arthritis by promoting the IRF4-SHIP1 signaling pathway - Nature.com - January 27th, 2025
- Rheumatoid Arthritis Basics: Overview, Symptoms, and Causes - January 27th, 2025
- 8 Things You Should Do in Your 20s, 30s, and 40s to Prevent Joint Pain Later in Life - Self - January 27th, 2025
- 8 Natural Remedies to Relieve Join Pain and Improve Mobility - Health.com - January 27th, 2025
- East Texas vet tells what to watch for during cold weather in arthritic pets - KTRE - January 27th, 2025
- Research Shows a Link Between Inflammation in the Gut and Rheumatoid Arthritis - Health Central - January 27th, 2025
- Address to the Business Community Attend the Arthritis Foundation Event - TAPinto.net - January 27th, 2025
- The journey of 2-year-old with arthritis - PAHomePage.com - January 27th, 2025
- East Texas vet tells what to watch for during cold weather in arthritic pets - KLTV - January 27th, 2025
- Four tips for managing rheumatoid arthritis in the winter - Yahoo Lifestyle UK - January 27th, 2025
- Living with arthritis: Here's how diet, exercise, and daily habits can ease the pain - Moneycontrol - January 27th, 2025
- Sichuan wildlife park peddles tiger urine, claiming efficacy for rheumatoid arthritis, other conditions - Global Times - January 27th, 2025
- Non-surgical option to ease knee arthritis - The Week - January 27th, 2025
- Ease arthritis pain by adding 1 juice to your diet - Surrey Live - January 27th, 2025
- Four tips for managing rheumatoid arthritis in the winter - Yahoo News UK - January 27th, 2025
- Drinking one juice can ease arthritis pain, studies reveal - Daily Record - January 27th, 2025
- Annual Health Observances | NIAMS - National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) - October 6th, 2024
- Obesity dampens rheumatoid arthritis treatment effectiveness, satisfaction - Healio - October 6th, 2024
- Patient Perspectives: Finding Grace While Living With Rheumatoid Arthritis - Rheumatology Advisor - October 6th, 2024
- Rheumatoid arthritis tied to heavy economic and human burdens - Medical Xpress - October 6th, 2024
- Dual therapy can have synergistic effect in difficult-to-treat inflammatory diseases - Healio - October 6th, 2024
- Hand-Held Scanner Could Transform Cancer and Arthritis Diagnosis - Technology Networks - October 6th, 2024
- Medical imaging breakthrough could transform cancer and arthritis diagnosis - University College London - October 6th, 2024
- Citryll and leading rheumatology centres receive - GlobeNewswire - October 6th, 2024
- Its going to be ubiquitous: Weight loss drugs may aid rheumatic disease treatment - Healio - October 6th, 2024
- Comorbidities Associated With Psoriasis: 5 Things to Know - Medscape - October 6th, 2024
- Opinion: Let's treat arthritis with the seriousness it deserves - Vancouver Sun - October 6th, 2024
- New handheld scanner technology could transform cancer and arthritis diagnosis - The Engineer - October 6th, 2024
- Stem cell therapy for osteoarthritis: Functional cartilage regeneration using 3d bioprinting technology - Open Access Government - October 6th, 2024
- Handheld scanner could transform cancer and arthritis diagnosis study - The Independent - October 6th, 2024
- Ankylosing Spondylitis and Self-Care: 6 Science-Backed Tips - Everyday Health - October 6th, 2024
- From a Labrador with arthritis to a goldfishs lifespan your pet queries answered... - The Sun - October 6th, 2024
- 15 Home Essentials That Make Life Easier If You Have Arthritis - HuffPost - September 21st, 2024
- Gout, a painful form of arthritis, is on the rise. Avoiding red meat and alcohol can help. - Yahoo Life - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pain - MedicineNet - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - U.S. News & World Report - September 21st, 2024
- Arthritis can flare up in colder weather: Tips to easing the pan - Medical Xpress - September 21st, 2024
- See how Waymo is bringing Arthritis Foundation of Arizona families to the ballpark - ABC15 Arizona in Phoenix - September 21st, 2024
- Prevalence of Loneliness in Inflammatory Arthritis and its Association with Disease Activity - Physician's Weekly - September 21st, 2024
- Psoriatic Arthritis and Gluten: Whats the Link? - Health Central - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - Southernminn.com - September 21st, 2024
- 6 Knee Injuries That Can Cause Arthritis - Health News Hub - September 21st, 2024
- The Best Rheumatoid Arthritis Self-Care Tips To Soothe Painful Joints and Improve Mobility - Yahoo Life - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - El Paso Inc. - September 21st, 2024
- Shifting kneecap in kids? Early ligament repair can prevent arthritis in young Age: Experts - The Times of India - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - Shelbynews - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - Citizentribune - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - News-Daily.com - September 21st, 2024
- Casavant: Access to virtual care at risk for millions of arthritis patients - Daily Independent - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - Avery Journal Times - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - The Elkhart Truth - September 21st, 2024
- What To Eat (And Skip) on a Rheumatoid Arthritis Diet To Reduce Painful Inflammation - Woman's World - September 21st, 2024
- Tiny knee bone linked to arthritis may have helped humans walk upright, scientists suggest - Sky News - September 13th, 2024
- Medical Marijuana Helps People With Arthritis And Other Rheumatic Conditions Reduce Use Of Opioids And Other Medications, Study Shows - Marijuana... - September 13th, 2024
- My 'stomach bug' turned out to be an agonising pain condition that left me wheelchair bound within four years - Daily Mail - September 13th, 2024
- Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis - Nature.com - September 13th, 2024